Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant.

NCT ID: NCT01860716

Last Updated: 2013-05-23

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2013-12-31

Brief Summary

Impact of melatonin on organ donor pretreatment and liver transplant recipient: prospective, randomized, double-blind trial.

OBJECTIVES. To establish the efficacy of the melatonin administered to encephalic death donors (EDD) in liver transplantation. The aim is to improve the functional quality of the retrieved organs, attenuate lesions and ischemia-reperfusion mediators, and provide grafts with greater resistance to post-transplant aggression.

METHODOLOGY. Prospective, randomized, double-blind, pilot trial to evaluate preconditioning with melatonin versus placebo in EDDs. Two groups, melatonin and control-placebo, n=30 per group. Administration to donor via NG tube of 30mg of melatonin or placebo (lactose) upon inclusion in the trial, 60 minutes prior to commencement of surgery and following laparotomy during extraction. Evaluation of response to treatment: A) Conventional clinical, hemodynamic, analytical and histopathological parameters in donor and recipient. B) Plasma determinations for: oxidative/nitrosative stress; acute phase proteins; cellular and humoral immunity; NT-proBNP and cystatin C; endocrine profile; melatonin levels. C) Determinations in liver tissue: quantification of malonyldialdehyde-4hydroxyalkenals and protein carbonyl content; cellular and mitochondrial membrane fluidity; markers of tissue-vascular damage and proliferation: transforming growth factor-beta (TGF-β); hypoxia-inducible factor (HIF) and vascular endothelial growth factor (VEGF). Data will be analyzed following a prospectively define plan and by intention-to-treat analysis.

Detailed Description

This study will be done in the Hospital Clinico Lozano Blesa (Zaragoza, Spain), promoted by the Health Science Aragon Institute and its principal investigator is F. Agustín García Gil (Surgical Service). It will start in April-May 2013 and will finish 12 months later approximately. The study sponsor is I+CS (Aragon Institute of Health Sciences).

Conditions

Evidence of Liver Transplantation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Solution for infusion

Solution for infusion administrated via nasogastric tube

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Melatonin

30 mg melatonin administrated via nasogastric tube in the Intensive Care Unit when included in the study and 30 mg melatonin 60 minutes before transfer to the operating room.

Group Type: EXPERIMENTAL

Melatonin

Intervention Type: DRUG

Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.

Interventions

Melatonin

Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

Circadin (Neurim Pharmaceuticals)

Eligibility Criteria

Inclusion Criteria

A) Donors

1. Encephalic-death (ED) organ donor who is situated in the ICUs of accredited hospitals in Zaragoza and meets each and every one of the following criteria.

2. Being 16 years old or older.

3. Informed consent for the donation signed by the immediate family.

4. Informed consent for inclusion of the donor in the study .

5. Receive intensive treatment and standard maintenance of the donor in ED, in accordance with universally accepted protocols of the Organizacion Nacional de Trasplantes (ONT), of the Aragon Autonomous Transplant Coordination, and of the ICUs and the participating hospitals in the study.

B) Liver transplant recipients

1. Being 18 years old or older and being less than 68 years of age.

2. Informed consent for the procedure of LT signed.

3. Informed consent for patient inclusion in the study, signed the same day that consent to the LT.

Exclusion Criteria

A) Donors

A potential encephalic-death organ donor will not be included in the study if either of the following criteria:

1. Absence of either signed informed consent: for organ donation or for inclusion in the study.

2. No standard concomitant treatment and management of donor in ED.

B) Liver transplant recipients

1. Absence of either signed informed consent: for liver transplantation or for inclusion in the study.

2. Split, domino or multiorgan transplantation.

3. Grafts removed by other surgical teams.

4. Pregnant women or fertile not using contraceptive measures highly effective.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 68 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fondo de Investigacion Sanitaria

OTHER

Sponsor Role: collaborator

Aragon Institute of Health Sciences

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Francisco A. García-Gil, Physician

Role: PRINCIPAL_INVESTIGATOR

Hospital Clínico Universitario Lozano Blesa

Locations

Hospital Clínico Universitario Lozano Blesa

Zaragoza, Zaragoza, Spain

Countries

Spain

Facility Contacts

Francisco A. García-Gil, Physician

Role: primary

agarciagil@telefonica.net

0034976765700

Other Identifiers

PI10/02877

Identifier Type: -

Identifier Source: org_study_id